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BACKGROUND
In 2002 the COSMIC team at the Sanger Center in the United Kingdom identified frequent gain-offunction BRAF(V600E) mutations in melanoma (1) . Oncogenic mutations in the BRAF gene induce constitutive activation of its serine/threonine kinase activity and activation of the downstream mitogenactivated protein kinase (MAPK) signal transduction pathway. BRAF mutations are also documented in other malignancies, for example, papillary thyroid carcinomas (2) , hairy cell leukemias (3), nonsmall cell lung (4) and colorectal carcinomas (5) , thus highlighting this pathway as a key oncogenic driver in multiple anatomical tissues. Overall, BRAF(V600E) is the most prevalent missense mutation in human cancer that in addition can be targeted therapeutically.
Identification of oncogenic driver mutations in human cancers such as the KRAS and BRAF genes has accelerated the development of small molecule inhibitors along the RAS-RAF-MEK-MAPK signaling pathway. Importantly, the first-in-class BRAF-specific inhibitor vemurafenib (PLX4032) (6) was approved in 2011 and extends melanoma survival by 4-6 months compared to standard chemotherapy (7, 8) . Despite dramatic initial tumor shrinkage in patients with melanoma, long-term efficacy is thwarted due to emergence of drug resistance (9) . Alternative BRAF inhibitors, such as dabrafenib (GSK2118436 (10)), have shown similar response in melanoma patients followed by drug resistance and progression (11) . However, the anti-tumor activity of vemurafenib in patients with BRAF(V600E)-mutant papillary thyroid or colorectal cancers remains dismal, possibly due to existence of compensatory pathways, such as EGFR signaling (12) . Targeting the downstream target MEK1/2 has shown survival benefit in melanoma patients (13) and has been approved for treatment of patients with BRAF mutant melanoma. Collectively, targeted inhibition of the BRAF-MEK axis in malignant melanoma has extended patient survival, but responses are limited by emergence of drug resistance. Understanding how to prevent onset of resistance to oncogene targeted therapies and increase their initial therapeutic efficacy may provide key insights towards developing sustainable treatment against BRAF-mutant cancers in general and melanoma in particular. Because cancer cells have distinct metabolic demands from non-malignant cells, combinatorial inhibition of tumor-critical metabolic pathways is an attractive therapeutic approach to extend the usefulness of BRAF and MEK targeted therapies.
Metabolic shift in the transition from normal to cancer cell
In normal aerobic cells, glucose is the quintessential nutrient for energy production (Figure 1 ).
Metabolic breakdown of glucose (glycolysis) drives catabolic ATP production through a pathway that couples the Krebs/tricarboxylic acid (TCA) cycle with oxidative phosphorylation (OXPHOS). In essence, glycolysis produces pyruvate, which is transported to the mitochondria for oxidation into acetyl-CoA to fuel the TCA cycle. Successive oxidation of acetate in the TCA cycle leads to transfer of (15) .
Role of mitochondrial oxidative phosphorylation in cancer
Despite the prevailing emphasis on glycolysis in cancer metabolism, leukemias, prostate and breast cancers, as well as melanomas, require oxidative phosphorylation for their growth (16, 17, 18, 19) . In fact, some melanomas have significantly higher oxygen consumption than melanocytes (20) , indicating that OXPHOS itself may be an important metabolic target in some tumor contexts.
Moreover, inhibition of OXPHOS using elesclomol provokes apoptosis initially, while prolonged in vitro selective growth drives enhanced glycolysis. Hence, this study indicates that melanomas are acutely dependent on OXPHOS, while they are able to adapt to alternate metabolism. Using a mouse malignant melanoma model it has also been demonstrated that selectively depleting mitochondrial DNA (mtDNA), which encodes key components of the electron transport chain and thus compromises OXPHOS, delays subcutaneous tumor growth and prevent metastasis (21) . Similar results have been reported in a human breast cancer cell line (22) . Together these observations suggest that in addition to a general glycolytic phenotype due to anabolic demands, there is significant heterogeneity in the metabolic requirements of cancer cells. Therefore, a molecular understanding of how OXPHOS is regulated by oncogenic pathways is critical for its rational therapeutic exploit in cancer treatment. 
Activation of oncogenes and the shift to anabolic metabolism
Normal cells have a number of programs in place to reduce the likelihood for renegade growth (23) . In particular oncogene-induced senescence (OIS) provides such a barrier that leads to premature terminal growth arrest in response to mutant RAS and RAF, which depends on intact pRB (RB1) and p53 (TP53) pathways (24, 25, 26) . Interestingly, OIS by mutant RAS have been causally connected to induction of reactive oxygen species (ROS) (27) . Because the major source for ROS is OXPHOS, aberrant metabolism may be important in triggering OIS. In order to escape OIS, cells may choose to reroute their metabolism towards glycolytic metabolism to reduce ROS. A key regulator that drives this metabolic shift is hypoxia-induced factor 1α (HIF1α), which in response to low oxygen gets stabilized and activates a program that reduces mitochondrial utilization through its function as a transcription factor. Specifically, HIF1α upregulates pyruvate dehydrogenase kinase 1 (PDK1) (28, 29) that inactivates the pyruvate kinase complex, which is responsible for conversion of pyruvate to the main fuel for the TCA cycle: acetyl-CoA. Consistent with reducing OIS during hypoxic conditions (27) , HIF1α acts as an oxygen sensor and drive cellular metabolism towards anabolic pathways, which is in line with Warburg's original observation (14) . Hence, adaptation to oncogenic mutations along the RAS-RAF-MEK pathway is causally linked to the metabolic shift observed in cancer cells.
Oncogenic BRAF(V600E) and senescence-like benign nevi
Seemingly a paradox at first, benign nevi was found to harbor BRAF(V600E) mutations in a frequency similar to that of malignant melanomas (30) , offering some doubts as to its function as a cancer driver.
However, subsequent functional studies using various models substantiated this oncogene as a melanoma formation driver and verified it as a key therapeutic target (31, 32, 33, 34, 35) . Additionally, benign nevi have been demonstrated to exhibit hallmarks of OIS due to BRAF(V600E) activation (36) , highlighting that fail-safe barriers to tumorigenesis could be visualized in vivo. Because oncogenic BRAF is not sufficient to induce tumorigenesis in the absence of additional genetic alterations, the vast majority of nevi represent an end-stage of local melanocyte proliferation. Hence, co-operating mutations such as PTEN loss-of-function mutations, which lead to constitutive activation of the phosphatidylinositol 3-kinase (PI3K) v-akt murine thymoma viral oncogene (AKT)-mammalian target of rapamycin (mTOR) pathway, is found in a substantial fraction of melanomas co-existing with mutant BRAF (37) . Activation of the PI3K-mTOR pathway promote glycolysis by inducting the activity of HIF1α (38) , and therefore also indicates a consistent "Warburg effect" to allow for continued proliferation through bypassing OIS (39 (40) . This effect was correlated to suppression of the PDH-inhibitory enzyme pyruvate dehydrogenase kinase 1 (PDK1) and induction of the PDH-activating enzyme pyruvate dehydrogenase phosphatase 2 (PDP2). Reversal of PDH activation enabled bypass of OIS and tumorigenic growth. Whether HIF1α activation would enable bypass of OIS in this context was not analyzed, but since PDK1 is a bona fide downstream target gene (28, 29) , it seems highly plausible and would favor Warburg's original observation. Nonetheless, these data highlight that BRAF(V600E)
as an oncogene provoke OIS that requires coordination of metabolic re-programming to drive tumor initiation.
The oncogene MITF controls melanocyte development and melanoma metabolism
It is of critical importance to determine whether the effects of oncogene-targeted therapies intersects with the inherent cellular wiring of cancer cells to provide feedback control that limits or affords therapeutic effects. Given that melanoma cells are inherently sensitive to therapeutic inhibition of BRAF(V600E)-targeted agents, while papillary thyroid, non-small cell lung and colorectal carcinomas are not, a plausible explanation is that the metabolic state is dramatically different between these tumor cell-types.
Among mutations that co-segregate and co-operate with BRAF(V600E) in melanoma is amplification of the melanocyte master regulator microphthalmia-associated transcription factor (MITF) (35) . MITF is required for melanocyte development (41, 42) and regulates differentiationassociated programs of pigment synthesis and transport, as well as survival cues via the BCL2-famly of anti-apoptotic proteins (43, 44) . As an oncogene in melanoma, MITF is target of frequent gene amplification (35) and point mutation within sporadic and germ-line predisposition (45, 46) , which consistently lead to its elevated transcriptional activity. Surprisingly, MITF expression is often reduced in melanomas as compared to normal melanocytes, suggesting that it may have both pro-and anticancer effects depending on the context. MITF is regulated by multiple signaling pathways, including the metabolic regulator HIF1α. Specifically, HIF1α suppress expression of MITF in melanoma cells through its transcriptional effects on the repressor DEC1 (47, 48) . balance the effects of BRAF-and MEK-targeted therapies as a genuine melanoma oncogene and lineage master regulator (35, 45, 46) .
Control of metabolism by cellular sensing mechanisms
The general metabolic sensing pathway in cells involves the tumor suppressor LKB1 acting on AMPK to respond to alterations in AMP/ATP levels in cells (52). Because activation of AMPK by LKB1 suppresses growth through inactivation of signaling onto mTOR when nutrients are scarce and ATP levels remains constant in cells, the activity is essentially affected by AMP levels alone. Interestingly, growth factors through their receptor tyrosine kinases and BRAF(V600E) have been shown to alter LKB1-AMPK signaling leading to reduced AMP sensing in melanoma cells (53, 54) . Specifically, downstream activation of MAPK and RSK have been shown to directly phosphorylate LKB1, leading to compromised ability to activate AMPK and thus decouples metabolic sensing (53) , which have been shown to exhort important effects on melanoma growth. In addition, during conditions when the RAS-RAF-MEK pathway is not constitutively activated or mutated, metabolic sensing through AMPK may lead to specific suppression of BRAF activity (55) . Hence, constitutive RAS-RAF-MEK signaling decouples energy sensing and may confer a sensitivity that offers mechanistic clues as to how cancer cells become sensitive to metabolic inhibition. Furthermore, mouse embryonic fibroblasts from LKB1 null mice are resistant to transformation by oncogenic RAS (56) , suggesting that LKB1 tumor suppressor function may in fact be required to drive the metabolic shift, which further places emphasis on the intersection between energy sensing and cancer development.
CLINICAL-TRANSLATIONAL ADVANCES
The growing recognition of altered metabolism as a hallmark of cancer has kindled interest in approaches that target metabolic pathways in combination with current available anti-cancer treatment modalities (23) . Chemical screens from over 20 years ago pointed to approaches to modulate OXPHOS, and given the recognition of this pathway in cancer, it will be worthwhile to reevaluate these data in light of the current era of genomics and targeted therapies. In particular, recent work has revealed a number of metabolic intervention opportunities with regard to forestall resistance to targeted therapy against mutant BRAF.
Targeting the metabolic shift that prevents OIS
BRAF mutations are detected in more than half of all melanomas, and NRAS is mutant in another 15-25%, underscoring the NRAS-BRAF axis as causally linked to melanocytes neoplasia. As outlined above, the source of the metabolic shift seen in human cancer cells is believed to be caused by OIS. (24, 25, 26) , reactivation of its function using a CDK4/6 inhibitor in melanoma cells have been shown to cause senescence (58) . A current active area of exploration is to determine whether CDK4/6 inhibitors can synergize with BRAF and MEK targeted agents to increase therapeutic efficacy (59) .
Deregulation of HIF1α contributes to the Warburg effect and consequently, therapeutic intervention of its activity and deregulated pathways that converge on its function is under intense scrutiny for cancer therapy (60) . This pursuit have recently been accelerated as mutations in key metabolic enzymes in the TCA cycle is believed to deregulate important metabolites, such as succinate, which is expected to increase the stability of HIF1α due to interfering with its oxygendependent degradation.
Additionally, as OIS induced by BRAF(V600E) was recently shown to be dependent on increased pyruvate oxidation suggests that targeting PDK may be one possible approach (40) . The preclinical data suggest that the generic inhibitor of PDK, dichroacetate (DCA) may in fact synergize with BRAF and MEK inhibitors to enhance the efficacy of inhibiting melanoma growth, even to resolve targeted drug resistance (40) .
Metabolic intervention strategies with regard to modulation of OXPHOS
The recognition that melanoma cells may adapt to BRAF and MEK inhibitors by driving oxidative metabolism through MITF-PGC1α suggests that targeting this pathway may be an alternative approach (50) . Specifically, mitochondrial uncoupling using poisons of the electron transport chain complexes, such as cyanide, do not have sufficient therapeutic index. The mitochondrial uncoupler, 2,4-dinitrophenol (2,4-DNP), which leads to dissemination of the proton gradient and generation of heat, has been used extensively used in diet pills but was discontinued due to dangerous side effects such as fatal hyperthermia. Although alternative mitochondrial uncouplers may be useful, they will likely lead to significant toxicities that possibly preclude their use for anti-cancer treatment regiments.
Well-tolerated inhibitors of OXPHOS may have greater therapeutic potential for cancer treatment, in particular the biguanides metformin and phenformin used in treatment of type II diabetes.
These drugs are believed to act by inhibiting complex I of the electron transport chain (61) . While biguanides have demonstrated anti-cancer activity both in vitro and in vivo (62) , the efficacy of 
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